Journal
CELL DEATH & DISEASE
Volume 4, Issue -, Pages -Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/cddis.2013.61
Keywords
trichostatin A; Nutlin-3; p53; p21; cancer therapy; iPS cell generation
Categories
Funding
- Swedish Cancer Society (Cancerfonden)
- Swedish Research Council (Vetenskapsradet)
- Association for International Cancer Research (AICR) [10-0043]
- Cancer Research UK [C8/A6613]
- Karolinska Institutet
- Worldwide Cancer Research [13-0086] Funding Source: researchfish
Ask authors/readers for more resources
Nutlin-3 selectively activates p53 by inhibiting the interaction of this tumor suppressor with its negative regulator murine double minute 2 (mdm2), while trichostatin A (TSA) is one of the most potent histone deacetylase (HDAC) inhibitors currently available. As both Nutlin-3 and TSA increase the levels of the cell cycle inhibitor p21(cip1/waf1) in cells, we investigated whether a combination of these compounds would further augment p21 levels. Contrary to expectations, we found that short-term exposure to Nutlin-3 and TSA in combination did not have an additive effect on p21 expression. Instead, we observed that activation of p53 prevented the ability of TSA to increase p21 levels. Furthermore, TSA inhibited Nutlin-3-induced expression of p53-dependent mRNAs including P21. This negative effect of TSA on Nutlin-3 was significantly less pronounced in the case of hdm2, another p53 downstream target. Aside from suggesting a model to explain these incompatible effects of Nutlin-3 and TSA, we discuss the implications of our findings in cancer therapy and cell reprogramming. Cell Death and Disease (2013) 4, e533; doi:10.1038/cddis.2013.61; published online 7 March 2013
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available